53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
21.10.2025
Despite recent advances, there are no FDA-approved drugs for refractory/unexplained chronic cough (RCC/UCC). Numerous studies have demonstrated efficacy of cough suppression treatment (CST) by specialty-trained speech-language pathologists (SLPs). While recommended in consensus statements, there is a significant shortage of specialized SLPs to treat the estimated 5-7 million cases of RCC/UCC in the US. We have integrated essential components of CST within the CoughPro cough monitoring application with the purpose of testing proof of concept for a CST digital therapeutic.
